{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:20:47Z","timestamp":1788283247736,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009001"],"award-info":[{"award-number":["T32CA009001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R03CA259659"],"award-info":[{"award-number":["R03CA259659"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA18610"],"award-info":[{"award-number":["UM1 CA18610"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA87969"],"award-info":[{"award-number":["P01 CA87969"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA176726"],"award-info":[{"award-number":["U01 CA176726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K99\/R00CA218681"],"award-info":[{"award-number":["K99\/R00CA218681"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA188943"],"award-info":[{"award-number":["R01CA188943"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA168758"],"award-info":[{"award-number":["R01CA168758"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186107"],"award-info":[{"award-number":["UM1 CA186107"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA87969"],"award-info":[{"award-number":["P01 CA87969"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA176726"],"award-info":[{"award-number":["U01 CA176726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258679"],"award-info":[{"award-number":["R01CA258679"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186107"],"award-info":[{"award-number":["UM1 CA186107"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA87969"],"award-info":[{"award-number":["P01 CA87969"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA176726"],"award-info":[{"award-number":["U01 CA176726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110320"],"award-info":[{"award-number":["W81XWH2110320"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"M. Barnard received support from the Karin Grunebaum Cancer Research Foundation."},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["9JK02"],"award-info":[{"award-number":["9JK02"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,9,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-hormonal intrauterine devices (IUDs) create an inflammatory uterine environment while oral contraceptives (OC) suppress ovulation and have different associations with ovarian cancer risk. We have evaluated the associations of\u00a0these two contraceptive exposures with ovarian tumor immune infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study assessed associations of IUD and OC use with tumor immune features via multiplex immunofluorescence in 24 ovarian tumor tissue microarrays from four case-control and two cohort studies. Multivariable-adjusted beta-binomial models estimated the odds of tumor T cell positivity by contraceptive history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High-grade serous tumors had the highest percentage of tumor cells positive for total T cells (CD3\n                      <jats:sup>+<\/jats:sup>\n                      mean=3.4%, SD\u2009=\u20096.1) and each T cell subtype. Ever (vs. never) IUD use was modestly associated with increased cytotoxic T cell infiltration (CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      OR:1.14, 95% CI:0.99\u20131.32), which was stronger among those with a history of endometriosis, postmenopausal women, and smokers. Conversely, OC use \u22651 year (vs. never) was associated with lower cytotoxic T cell odds (CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      OR:0.89, 95% CI:0.79\u20131.00;\n                      <jats:italic>p<\/jats:italic>\n                      -het=0.008). Increased odds of terminal T cell exhaustion were observed for IUD use only (CD3\n                      <jats:sup>+<\/jats:sup>\n                      PD1\n                      <jats:sup>+<\/jats:sup>\n                      TIM3\n                      <jats:sup>+<\/jats:sup>\n                      OR:1.53, 95% CI:0.99\u20132.36), which was stronger among those who had ever used genital powder or BMI\u2009&gt;\u200925\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-diagnostic contraception use may influence ovarian tumor immunity and may modulate cancer susceptibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03508-9","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:04:08Z","timestamp":1782579848000},"page":"972-982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-8359","authenticated-orcid":false,"given":"Jennifer M.","family":"Mongiovi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Babic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-4477","authenticated-orcid":false,"given":"Mary K.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison F.","family":"Vitonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-4655","authenticated-orcid":false,"given":"Mollie","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Rinda","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-4074","authenticated-orcid":false,"given":"Jose R.","family":"Conejo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-8600","authenticated-orcid":false,"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-9339","authenticated-orcid":false,"given":"Joellen M.","family":"Schildkraut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesmary","family":"Modugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke L.","family":"Fridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-7046","authenticated-orcid":false,"given":"Shelley S.","family":"Tworoger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"3508_CR1","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","volume":"34","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34:2888\u201398.","journal-title":"J Clin Oncol"},{"key":"3508_CR2","first-page":"1","volume":"212","author":"LJ Havrilesky","year":"2013","unstructured":"Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep\/Technol Assess. 2013;212:1\u2013514.","journal-title":"Evid Rep\/Technol Assess"},{"key":"3508_CR3","unstructured":"IOM (Institute of Medicine). Clinical preventive services for women: closing the gaps. The National Academies Press, Washington, DC; 2011."},{"key":"3508_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/AOG.0000000000003463","volume":"134","author":"LJ Wheeler","year":"2019","unstructured":"Wheeler LJ, Desanto K, Teal SB, Sheeder J, Guntupalli SR. Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2019;134:791\u2013800.","journal-title":"Obstet Gynecol"},{"key":"3508_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","volume":"149","author":"M Jareid","year":"2018","unstructured":"Jareid M, Thalabard JC, Aarflot M, B\u00f8velstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149:127\u201332.","journal-title":"Gynecol Oncol"},{"key":"3508_CR6","first-page":"3670","volume":"49","author":"XO Shu","year":"1989","unstructured":"Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 1989;49:3670\u20134.","journal-title":"Cancer Res"},{"key":"3508_CR7","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1158\/1055-9965.EPI-22-1285","volume":"32","author":"CA Hathaway","year":"2023","unstructured":"Hathaway CA, Conejo-Garcia JR, Fridley BL, Rosner B, Saeed-Vafa D, Moran Segura C, et al. Measurement of ovarian tumor immune profiles by multiplex immunohistochemistry: implications for epidemiologic studies. Cancer Epidemiol Biomark Prev. 2023;32:848\u201353.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3508_CR8","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.contraception.2007.01.020","volume":"75","author":"ME Ortiz","year":"2007","unstructured":"Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75:S16\u201330.","journal-title":"Contraception"},{"key":"3508_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/AOG.0000000000002307","volume":"130","author":"VK Cortessis","year":"2017","unstructured":"Cortessis VK, Barrett M, Brown Wade N, Enebish T, Perrigo JL, Tobin J, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017;130:1226\u201336.","journal-title":"Obstet Gynecol"},{"key":"3508_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/bjc.1994.369","volume":"70","author":"F Parazzini","year":"1994","unstructured":"Parazzini F, La Vecchia C, Moroni S. Intrauterine device use and risk of endometrial cancer. Br J Cancer. 1994;70:672\u20133.","journal-title":"Br J Cancer"},{"key":"3508_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/ijc.2910540607","volume":"54","author":"X Castellsagu\u00e9","year":"1993","unstructured":"Castellsagu\u00e9 X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer. 1993;54:911\u20136.","journal-title":"Int J Cancer"},{"key":"3508_CR12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1042\/bst0051563","volume":"5","author":"L Myatt","year":"1977","unstructured":"Myatt L, Elder MG, Chaudhuri G, Lim L. The rat uterine oestrogen receptor in relation to intra-uterine devices and the oestrous cycle [proceedings]. Biochem. Soc Trans. 1977;5:1563\u20134.","journal-title":"Biochem. Soc Trans"},{"key":"3508_CR13","doi-asserted-by":"crossref","unstructured":"Mongiovi JM, Babic A, Sasamoto N, Shafrir AL, Huang T, Townsend MK, et al. Associations between common contraceptive use and circulating inflammatory biomarkers. Am J Epidemiol. 2024;194:85\u201394.","DOI":"10.1093\/aje\/kwae135"},{"key":"3508_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1158\/1055-9965.EPI-16-0120","volume":"25","author":"F Zeng","year":"2016","unstructured":"Zeng F, Wei H, Yeoh E, Zhang Z, Ren ZF, Colditz GA, et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev. 2016;25:1231\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3508_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0020-7292(81)90051-5","volume":"19","author":"M Shaarawy","year":"1981","unstructured":"Shaarawy M, Naguib YA, El Safory LS, Abdel Kader MM. Reactive protein and immunoglobulin levels in women using intrauterine devices. Int J Gynaecol Obstet. 1981;19:125\u201331.","journal-title":"Int J Gynaecol Obstet"},{"key":"3508_CR16","first-page":"239","volume":"3","author":"D Wiedermann","year":"1980","unstructured":"Wiedermann D, Kr\u00edz J, C\u00eddl K. Specific serum protein levels in women using intrauterine contraceptive device. Czech Med. 1980;3:239\u201347.","journal-title":"Czech Med"},{"key":"3508_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-688","volume":"14","author":"JM Schildkraut","year":"2014","unstructured":"Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, et al. A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer. 2014;14:688.","journal-title":"BMC Cancer"},{"key":"3508_CR18","first-page":"1117","volume":"8","author":"BF Hankey","year":"1999","unstructured":"Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomark Prev. 1999;8:1117\u201321.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3508_CR19","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s10552-012-0076-x","volume":"23","author":"C Bodelon","year":"2012","unstructured":"Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23:1985\u201394.","journal-title":"Cancer Causes Control"},{"key":"3508_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/EDE.0b013e3182456ad3","volume":"23","author":"WH Lo-Ciganic","year":"2012","unstructured":"Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012;23:311\u20139.","journal-title":"Epidemiology"},{"key":"3508_CR21","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1158\/0008-5472.CAN-04-3885","volume":"65","author":"KL Terry","year":"2005","unstructured":"Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res. 2005;65:5974\u201381.","journal-title":"Cancer Res"},{"key":"3508_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrc1608","volume":"5","author":"GA Colditz","year":"2005","unstructured":"Colditz GA, Hankinson SE. The Nurses\u2019 Health Study: lifestyle and health among women. Nat Rev Cancer. 2005;5:388\u201396.","journal-title":"Nat Rev Cancer"},{"key":"3508_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/ije\/25.1.122","volume":"25","author":"LM Troy","year":"1996","unstructured":"Troy LM, Michels KB, Hunter DJ, Spiegelman D, Manson JE, Colditz GA, et al. Self-reported birthweight and history of having been breastfed among younger women: an assessment of validity. Int J Epidemiol. 1996;25:122\u20137.","journal-title":"Int J Epidemiol"},{"key":"3508_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/oxfordjournals.aje.a113804","volume":"119","author":"MJ Stampfer","year":"1984","unstructured":"Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol. 1984;119:837\u20139.","journal-title":"Am J Epidemiol"},{"key":"3508_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10552-022-01660-0","volume":"34","author":"JM Schildkraut","year":"2023","unstructured":"Schildkraut JM, Johnson C, Dempsey LF, Qin B, Terry P, Akonde M, et al. Survival of epithelial ovarian cancer in Black women: a society to cell approach in the African American cancer epidemiology study (AACES). Cancer Causes Control. 2023;34:251\u201365.","journal-title":"Cancer Causes Control"},{"key":"3508_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","volume":"151","author":"LC Peres","year":"2018","unstructured":"Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, et al. Histotype classification of ovarian carcinoma: a comparison of approaches. Gynecol Oncol. 2018;151:53\u201360.","journal-title":"Gynecol Oncol"},{"key":"3508_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:e173290.","journal-title":"JAMA Oncol"},{"key":"3508_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1055-9965.EPI-17-0609","volume":"27","author":"HR Harris","year":"2018","unstructured":"Harris HR, Rice MS, Shafrir AL, Poole EM, Gupta M, Hecht JL, et al. Lifestyle and reproductive factors and ovarian cancer risk by p53 and MAPK expression. Cancer Epidemiol Biomark Prev. 2018;27:96\u2013102.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3508_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ygyno.2016.09.024","volume":"143","author":"AL Shafrir","year":"2016","unstructured":"Shafrir AL, Rice MS, Gupta M, Terry KL, Rosner BA, Tamimi RM, et al. The association between reproductive and hormonal factors and ovarian cancer by estrogen-\u03b1 and progesterone receptor status. Gynecol Oncol. 2016;143:628\u201335.","journal-title":"Gynecol Oncol"},{"key":"3508_CR30","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1158\/1055-9965.EPI-18-0346","volume":"27","author":"ME Barnard","year":"2018","unstructured":"Barnard ME, Hecht JL, Rice MS, Gupta M, Harris HR, Eliassen AH, et al. Anti-inflammatory drug use and ovarian cancer risk by COX1\/COX2 expression and infiltration of tumor-associated macrophages. Cancer Epidemiol Biomark Prev. 2018;27:1509\u201317.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3508_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1158\/1055-9965.EPI-24-1414","volume":"34","author":"JM Mongiovi","year":"2025","unstructured":"Mongiovi JM, Townsend MK, Vitonis AF, Harris HR, Doherty JA, Babic A, et al. Associations between parity, history of breastfeeding, and t-cell profile of ovarian tumors. Cancer Epidemiol Biomark Prev. 2025;34:550\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3508_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbi.2023.08.006","volume":"114","author":"CA Hathaway","year":"2023","unstructured":"Hathaway CA, Townsend MK, Conejo-Garcia JR, Fridley BL, Moran Segura C, Nguyen JV, et al. The relationship of lifetime history of depression on the ovarian tumor immune microenvironment. Brain Behav, Immun. 2023;114:52\u201360.","journal-title":"Brain Behav, Immun"},{"key":"3508_CR33","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.3390\/cancers13123031","volume":"13","author":"CM Wilson","year":"2021","unstructured":"Wilson CM, Ospina OE, Townsend MK, Nguyen J, Moran Segura C, Schildkraut JM, et al. Challenges and opportunities in the statistical analysis of multiplex immunofluorescence data. Cancers. 2021;13:3031.","journal-title":"Cancers"},{"key":"3508_CR34","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1067\/mob.2002.128091","volume":"187","author":"JB Stanford","year":"2002","unstructured":"Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol. 2002;187:1699\u2013708.","journal-title":"Am J Obstet Gynecol"},{"key":"3508_CR35","doi-asserted-by":"publisher","first-page":"45S","DOI":"10.1016\/S0010-7824(98)00082-1","volume":"58","author":"DR Mishell Jr","year":"1998","unstructured":"Mishell DR Jr. Intrauterine devices: mechanisms of action, safety, and efficacy. Contraception. 1998;58:45S\u201353S.","journal-title":"Contraception"},{"key":"3508_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/00016349409013411","volume":"73","author":"AL Wollen","year":"1994","unstructured":"Wollen AL, Sandvei R, Mork S, Marandon JL, Matre R. In situ characterization of leukocytes in the fallopian tube in women with or without an intrauterine contraceptive device. Acta Obstet Gynecol Scand. 1994;73:103\u201312.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"3508_CR37","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/S0002-9378(84)90446-0","volume":"148","author":"A Tursi","year":"1984","unstructured":"Tursi A, Mastrorilli A, Ribatti D, Loiudice L, Contino R, Claudatus J. Possible role of mast cells in the mechanism of action of intrauterine contraceptive devices. Am J Obstet Gynecol. 1984;148:1064\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"3508_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0010-7824(90)90090-I","volume":"42","author":"L Randi\u0107","year":"1990","unstructured":"Randi\u0107 L, Haller H, Su\u015ba M, Rukavina D. Cells adherent to copper-bearing intrauterine contraceptive devices determined by monoclonal antibodies. Contraception. 1990;42:35\u201342.","journal-title":"Contraception"},{"key":"3508_CR39","doi-asserted-by":"crossref","unstructured":"Serrano MG, Edwards D, Ahmed K, Bailey VC, Beksinska M, Edupuganti L, et al. Effect of contraceptive methods on the vaginal microbiome and host immune factors. Contraception. 2025;148:110936.","DOI":"10.1016\/j.contraception.2025.110936"},{"key":"3508_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13542","volume":"88","author":"N Radzey","year":"2022","unstructured":"Radzey N, Harryparsad R, Meyer B, Chen PL, Gao X, Morrison C, et al. Genital inflammatory status and the innate immune response to contraceptive initiation. Am J Reprod Immunol. 2022;88:e13542.","journal-title":"Am J Reprod Immunol"},{"key":"3508_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.contraception.2016.06.021","volume":"94","author":"CR Kim","year":"2016","unstructured":"Kim CR, Martinez-Maza O, Magpantay L, Magyar C, Gornbein J, Rible R, et al. Immunologic evaluation of the endometrium with a levonorgestrel intrauterine device in solid organ transplant women and healthy controls. Contraception. 2016;94:534\u201340.","journal-title":"Contraception"},{"key":"3508_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979116","volume":"13","author":"L Fang","year":"2022","unstructured":"Fang L, Liu K, Liu C, Wang X, Ma W, Xu W, et al. Tumor accomplice: T cell exhaustion induced by chronic inflammation. Front Immunol. 2022;13:979116.","journal-title":"Front Immunol"},{"key":"3508_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/cancers10080251","volume":"10","author":"SS Savant","year":"2018","unstructured":"Savant SS, Sriramkumar S, O\u2019Hagan HM. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers. 2018;10:251.","journal-title":"Cancers"},{"key":"3508_CR44","doi-asserted-by":"publisher","first-page":"bqac098","DOI":"10.1210\/endocr\/bqac098","volume":"163","author":"LM Moldenhauer","year":"2022","unstructured":"Moldenhauer LM, Jin M, Wilson JJ, Green ES, Sharkey DJ, Salkeld MD, et al. Regulatory T cell proportion and phenotype are altered in women using oral contraception. Endocrinology. 2022;163:bqac098.","journal-title":"Endocrinology"},{"key":"3508_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0015-0282(02)03173-4","volume":"78","author":"L Auerbach","year":"2002","unstructured":"Auerbach L, Hafner T, Huber JC, Panzer S. Influence of low-dose oral contraception on peripheral blood lymphocyte subsets at particular phases of the hormonal cycle. Fertil Steril. 2002;78:83\u20139.","journal-title":"Fertil Steril"},{"key":"3508_CR46","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/aje\/kwz264","volume":"189","author":"T Huang","year":"2020","unstructured":"Huang T, Shafrir AL, Eliassen AH, Rexrode KM, Tworoger SS. Estimated number of lifetime ovulatory years and its determinants in relation to levels of circulating inflammatory biomarkers. Am J Epidemiol. 2020;189:660\u201370.","journal-title":"Am J Epidemiol"},{"key":"3508_CR47","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/ije\/dyw147","volume":"45","author":"Q Wang","year":"2016","unstructured":"Wang Q, W\u00fcrtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445\u201357.","journal-title":"Int J Epidemiol"},{"key":"3508_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/379501","volume":"2015","author":"AA Divani","year":"2015","unstructured":"Divani AA, Luo X, Datta YH, Flaherty JD, Panoskaltsis-Mortari A. Effect of oral and vaginal hormonal contraceptives on inflammatory blood biomarkers. Mediat Inflamm. 2015;2015:379501.","journal-title":"Mediat Inflamm"},{"key":"3508_CR49","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1093\/humrep\/des225","volume":"27","author":"T Piltonen","year":"2012","unstructured":"Piltonen T, Puurunen J, Hedberg P, Ruokonen A, Mutt SJ, Herzig KH, et al. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Hum Reprod. 2012;27:3046\u201356.","journal-title":"Hum Reprod"},{"key":"3508_CR50","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/AOG.0b013e31816a2476","volume":"111","author":"S Cauci","year":"2008","unstructured":"Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol. 2008;111:857\u201364.","journal-title":"Obstet Gynecol"},{"key":"3508_CR51","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","volume":"36","author":"D Wang","year":"2015","unstructured":"Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36:1085\u201393.","journal-title":"Carcinogenesis"},{"key":"3508_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"3508_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.it.2012.08.005","volume":"34","author":"PA Savage","year":"2013","unstructured":"Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 2013;34:33\u201340.","journal-title":"Trends Immunol"},{"key":"3508_CR54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"3508_CR55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/healthcare10020361","volume":"10","author":"H Park","year":"2022","unstructured":"Park H. Association between oral contraceptive use and the high-sensitivity C-reactive protein level in premenopausal Korean women. Healthcare. 2022;10:361.","journal-title":"Healthcare"},{"key":"3508_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1538-7836.2005.01690.x","volume":"4","author":"M van Rooijen","year":"2006","unstructured":"van Rooijen M, Hansson LO, Frosteg\u00e5rd J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006;4:77\u201382.","journal-title":"J Thromb Haemost"},{"key":"3508_CR57","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0024-3205(03)00425-9","volume":"73","author":"DM Dreon","year":"2003","unstructured":"Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci. 2003;73:1245\u201352.","journal-title":"Life Sci"},{"key":"3508_CR58","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/0008-5472.CAN-19-2850","volume":"80","author":"B Trabert","year":"2020","unstructured":"Trabert B, Tworoger SS, O\u2019Brien KM, Townsend MK, Fortner RT, Iversen ES, et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Res. 2020;80:1210\u20138.","journal-title":"Cancer Res"},{"key":"3508_CR59","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","volume":"4","author":"KA Michels","year":"2018","unstructured":"Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4:516\u201321.","journal-title":"JAMA Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03508-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03508-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03508-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:02:58Z","timestamp":1788282178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03508-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9,20]]}},"alternative-id":["3508"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03508-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LCP has received research funding from Bristol Myers Squibb, Karyopharm, and Janssen unrelated to this work. All other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study involved human participants, human data, and human tissue from the African American Cancer Epidemiology Study, Diseases of the Ovary and their Evaluation Study, Hormones and Ovarian Cancer Prediction Study, New England Case Control Study, Nurses\u2019 Health Study, and Nurses\u2019 Health Study II. All participants provided written informed consent or implied consent by completion of questionnaires. Study protocols were approved by the relevant Institutional Review Boards or ethics committees at each study site, as well as those of relevant registries where applicable. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}